News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Teva Releases Q4 2025 Aide Memoire

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
See all news items

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more Discover the world of Teva

Media Resources

at the office

Media Inquiries

Contact our corporate communications.
Learn more Media Inquiries

Media Kit

Files and resources for media use only
Download Teva Media Kit Media Kit

Financial Reports

View Teva financial news on our global website.
Learn more Financial Reports

Connect with us

Teva Social Media Guidelines.
Learn more Connect with us